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ItalyGene therapy clinical trials require rigorous non-clinical
studies in the most relevant models to assess the benefit-to-
risk ratio. To support the clinical development of gene therapy
for b-thalassemia, we performed in vitro and in vivo studies for
prediction of safety. First we developed newly GLOBE-derived
vectors that were tested for their transcriptional activity and
potential interference with the expression of surrounding
genes. Because these vectors did not show significant advan-
tages, GLOBE lentiviral vector (LV) was elected for further
safety characterization. To support the use of hematopoietic
stem cells (HSCs) transduced by GLOBE LV for the treatment
of b-thalassemia, we conducted toxicology, tumorigenicity,
and biodistribution studies in compliance with the OECD
Principles of Good Laboratory Practice. We demonstrated a
lack of toxicity and tumorigenic potential associated with
GLOBE LV-transduced cells. Vector integration site (IS)
studies demonstrated that both murine and human transduced
HSCs retain self-renewal capacity and generate new blood cell
progeny in the absence of clonal dominance. Moreover, IS anal-
ysis showed an absence of enrichment in cancer-related genes,
and the genes targeted by GLOBE LV in human HSCs are well
known sites of integration, as seen in other lentiviral gene ther-
apy trials, and have not been associated with clonal expansion.
Taken together, these integrated studies provide safety data
supporting the clinical application of GLOBE-mediated gene
therapy for b-thalassemia.Received 18 June 2018; accepted 7 September 2018;
https://doi.org/10.1016/j.omtm.2018.09.001.
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The development of retroviral vectors and optimized transduction
protocols has permitted gene transfer into hematopoietic stem and
progenitor cells (HSPCs), leading to the application and translation
of gene therapy strategies for a number of hematopoietic diseases
and leukodystrophies (reviewed in Dunbar et al.,1 Eichler et al.,2 Aiuti
et al.,3 Biffi et al.,4 and Ribeil et al.5).Molecular Therapy: Methods & Cl
This is an open access article undeb-Thalassemia, an inherited anemia characterized by reducedor absent
production of hemoglobin b chains, was one of the first candidate dis-
eases for gene therapy.6 Current management strategies for transfu-
sion-dependent thalassemia patients include blood transfusion, iron
chelation, and splenectomy. To date, allogeneic hematopoietic stem
cell transplantation (HSCT) is a cure only available for less than 30%
of patients.7 The benefits and limitations of current therapies for
b-thalassemia are well discussed by Cappellini et al.8 Ex vivo engineer-
ing of autologous HSPCs and administration of genetically modified
cells potentially represents a cure applicable to all patients regardless
of donor availability and free from transplant-related immunological
complications such as graft rejection and graft versus host disease.
The evidence gained from allogeneic HSCT indicates that 20%–30%
of donor chimerism can be curative in b-thalassemia patients and pro-
vides the rationale for a gene therapy approach.9 A recent study of 4 pa-
tients treated with HSCT demonstrated that, despite low myeloid
chimerism, the majority of circulating erythrocytes and progenitors
were of donor origin, suggesting that they have a selective advantage
in vivo.10 These data indicate that the proportion of genetically modi-
fied nucleated progenitor cells necessary to achieve a therapeutic level
of circulating red blood cells (RBCs) is within the frequency of gene
transfer by b-globin lentiviral vector (LV).10 Furthermore, non-clinical
studies conducted inhumanHSPCs in vitro andmurinemodels in vivo,
as well as the first clinical trial, have demonstrated the feasibility of the
gene therapy approach for the treatment of b-thalassemia.11,12
Despite the therapeutic success in clinical trials, lymphoproliferative
disorders and pre-malignant expansion of myeloid progenitorsinical Development Vol. 11 December 2018 ª 2018 The Author(s). 9
r the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Molecular Therapy: Methods & Clinical Developmenthave been reported in some patients treated with HSPCs transduced
with Moloney murine leukemia virus (MoMLV)-derived vectors,
where the retroviral vector was inserted into and activated a
proto-oncogene.13–15 Proviral elements that are involved in the tran-
scriptional regulation of the provirus can alter gene transcription; in
particular, elements present in the long terminal repeat (LTR) and
the splice donor sites normally used for splicing of viral transcripts.
Certain genotoxic events could lead to activation of the transforming
potential of a cellular proto-oncogene after integration of a retroviral
vector within or near the proto-oncogene, as reviewed by Naldini.16
Non-clinical studies showed that LVs are less likely to cause insertional
gene activation than retroviral vectors,17 although they can still cause
interference with normal gene regulation by inducing alterations in
transcriptional activity,18–21 aberrant splicing,22,23 and premature
transcript termination, as observed in thefirst clinical trial of gene ther-
apy for b-thalassemia.11 In this study, a clone harboring an insertion
site located within the proto-oncogene HMGA2 accounted for 30%
of all integration sites (ISs) in whole blood cells 3 years after gene ther-
apy. In the erythroid cells, the integration eventwas associatedwith the
expression of an HMGA2 transcript whose 30 UTR was replaced by
vector sequences. This chimeric transcript lacked the target site of
the repressive miRNA let-7, contributing to elevated HMGA2 expres-
sion together with an increase in the rate of transcriptional initiation.
Although the treated patient still remains healthy 11 years after ther-
apy, HMGA2 has been found to be de-regulated in some cancers.
Indeed, understanding the interactions between viral vectors and the
genome is instructive to assess the characteristics of transduced cells,
although the contributionof different clones tohematopoietic reconsti-
tution is not predictable from non-clinical studies. In gene therapy for
b-thalassemia, genotoxicity by trans-activation is expected to be very
limited because of the erythroid-restricted activity of promoter and/
or enhancer elements included in the self-inactivating vector and
because of the nature of the transferred gene (human b-globin chain).
No report of general toxicity or development of tumors associated with
the transfer of the human b-globin gene by LV has been reported so far
in a large number of non-clinical studies in mouse models.24–29 There-
fore, in view of future clinical application, safety studies of genetically
modified cells are preferably conducted following guidelines issued
by the regulatory agencies such as the European Medicines Agency
(EMA) and the US Food and Drug Administration (FDA). Crucial pa-
rameters to be assessed, when appropriate and feasible, include the
toxicity of the vector, the profile of vector integration, the in vivo bio-
distribution of transduced cells, and germline transmission. Although
in vitro tests for transducedHSPCs are defined, surrogate in vivo assays
may rely on transplantation of transduced cells in murine strains
and/or humanized immunodeficient mouse models.30–35
We have previously reported the development of GLOBE LV and
demonstrated expression of therapeutic levels of b-globin and long-
term correction with in vivo selection of genetically corrected
erythroid cells in a severe b-thalassemia intermedia mouse model26
as well as restoration of normal erythroid differentiation from trans-
duced CD34+ cells of b-thalassemia patients.36 In bothmouse and hu-10 Molecular Therapy: Methods & Clinical Development Vol. 11 Decemman cells, we obtained proof of efficacy with the achievement of ther-
apeutic levels of b-globin expression with a low vector copy number
and in the presence of a limited proportion of transduced HSPCs.
Tomove forwardwith clinical development, we identified the best-per-
forming b-globin LV by comparing GLOBE and newly derived vectors
for their transcriptional activity and potential interference with the
expression of surrounding genes. Furthermore, to support the use of
HSCs transduced by GLOBE LV for the treatment of b-thalassemia,
we followed the Guideline on the Non-clinical Studies Required before
First Clinical Use of Gene Therapy Medicinal Products (EMEA/
CHMP/GTWP/125459/2006), which defines scientific principles and
provides guidance to applicants developing gene therapy medicinal
products to facilitate a harmonized approach in the European Union
(EU). To guarantee quality, robustness, and traceability, we designed
and performed toxicology, tumorigenicity, and biodistribution studies
following the Guidelines for GLP (Good Laboratory Practice) in
compliance with the Italian GLP Regulations (DL 50, March 2, 2007;
G.U. 8, April 13, 2007) and the Organisation for Economic Co-opera-
tion and Development (OECD) Principles of GLP (as revised in 1997,
ENV/MC/CHEM(98)17). We evaluated the toxic and oncogenic po-
tential associated with the administration of HSPCs transduced with
a high dose of GLOBE LV to C57BL6/Hbbth3 mutant (th3/+) mice,
which represents the homologous disease model of severe thalassemia
intermedia. Moreover, to assess the effect of vector transduction on the
ability of human CD34+ cells to engraft and differentiate correctly in
the hematopoietic districts, we transplanted GLOBE LV-transduced
CD34+ cells into an immunodeficientmouse strain (non-obesediabetic
[NOD]/ NOD.Cg-Prkdcsid Il2rgtm1Wjl/SzJ [NSG]) and followed
their distribution and differentiation in hematopoietic and non-he-
matopoietic organs. Both studies were supplemented by vector IS anal-
ysis to corroborate safety predictions and HSC-related information.
Overall, our integrated approach, including in vitro and in vivo exper-
iments, provides results predictive of safety for b-thalassemia gene
therapy, complying with the applicable regulatory requirements for
advanced medicinal products.
RESULTS
Analysis of Perturbation of Expression in Genes Near or
Containing GLOBE LV
Changes in the expression of host genes flanking lentiviral ISs are a
safety concern when associated with changes in cell biology. To inves-
tigate the transcriptional perturbation of genes targeted by GLOBE
LV integrations, we utilized human erythroleukemia (HEL) cells,
which are permissive but negative for b-globin endogenous expres-
sion. HEL cells were transduced with three different LVs, specifically
GLOBE, GATA-GLOBE, and cHS4-GLOBE, a derived vector con-
taining the chicken HS4 insulator element in the 30 LTR, and grown
as single clones. Specifically, GATA-GLOBE is a derived vector con-
taining, in the 30 LTR, the erythroid enhancer GATA1 HS2 element,
potentially acting as an insulator, as we reported previously.37 The
strategy of including insulator elements in the vector LTR aimed to
provide protection from the effect of surrounding chromatin tober 2018
Figure 1. Toxicology and Tumorigenicity Study in a
Thalassemia Murine Model
(A) Experimental plan of the toxicology and tumorigenicity
study. Lin cells from donor C57BL6/Hbbth3 mutant
heterozygous (th3/+) mice were MOCK-transduced or
transduced with GLOBE LV at MOI 100 and incubated
overnight. The recipient mice were pre-treated with
busulfan (25 mg/kg/day for 4 days). Mice were intrave-
nously injected with a dose of 4  105 Lin cells/mouse.
Test group consisted of mice transplanted with GLOBE
LV-transduced Lin cells (th3/+ GLOBE LV). Control
groups consisted of mice pre-treated with busulfan and
transplanted with MOCK-transduced Lin cells (th3/+
MOCK) and age-matched untreated mice (th3/+).
Chimerism and cell origin were monitored using anti-
bodies specific for CD45.1 or CD45.2 surface antigen.
(B) Donor cell engraftment in male and female recipients
was determined by cytofluorimetric analysis for the
expression of CD45.1 in peripheral blood mononuclear
cells (PBMCs) at 16 weeks and 12 months after trans-
plantation (termination). Values are shown as mean ± SD.
Student’s t test was applied (*p < 0.05, ****p < 0.0001).
(C) Analysis of hematological reconstitution on peripheral
blood was assessed by cytofluorimetric analysis. Per-
centages of myeloid and lymphoid (B and T) cells were
evaluated by using antibodies against CD11b, B220, and
CD3, respectively. Values are shown as mean ± SD. The
GLOBE LV th3/+ group is shown in red, the MOCK th3/+
group in gray, and the th3/+ group in white. (D) VCN per
genome was evaluated in GLOBE LV th3/+ group males
and females. Values are shown as mean ± SD. (E) HGB
concentration was evaluated in all groups of mice. Values
are shown as mean ± SD. One-way ANOVA and post
hoc Bonferroni’s multiple comparisons were applied
(****p < 0.0001). (F) All animals were observed for signs of
ill health or overt toxicity from day1 until the end of the
study. Mortality was observed in the GLOBE LV th3/+ and
MOCK th3/+ groups from day 153 onward. 5 deaths
occurred in the GLOBE LV th3/+ group (circles). In the
MOCK th3/+ group (squares), two animals died. No
mortality was observed in the th3/+ group (triangles).
Survival fractions were calculated using the product limit
(Kaplan-Meier) method. Survival curves were compared
using the log rank test (also called the Mantel-Cox test).
No statistical difference was observed between the
groups.
www.moleculartherapy.orgintegrated proviruses to obtain reduction of variability and improve-
ment in the b-globin expression level in genetically modified cells.
Southern blot analysis of DNA extracted from clones showed that
the addition of GATA1-HS2 and cHS4 elements did not affect the
stability of the GLOBE LV (data not shown). The vector copy number
(VCN) per cell from single clones was measured, and no difference
was detected among the three vectors (Figure S1A), indicating a
similar transduction ability.
The expression of the b-globin transgene was analyzed by qPCR and
western blot in HEL cells induced to erythroid differentiation byMolecular Thhemin exposure and normalized for the VCN (Figures 1B and 1C).
No difference in transcriptional level was observed between
GLOBE and cHS4-GLOBE (Figure S1B), whereas GATA-GLOBE
LV produced 4-fold more b-globin transcript than GLOBE LV
(p < 0.001). However, the transcriptional difference between GLOBE
and GATA-GLOBE LV was not confirmed at the protein level
(Figure S1C).
To identify vector ISs, HEL cell clones were subjected to ligation-
mediated (LM)-PCR and DNA sequencing. Change in expression
level of target genes because of transcriptional activity at viral ISserapy: Methods & Clinical Development Vol. 11 December 2018 11
Molecular Therapy: Methods & Clinical Developmentwas analyzed by low-density array (LDA) real-time PCR technology
(Applied Biosystems). Genes sited within a window of 200 kb around
the IS were included in this analysis. The transcriptional activity of
genes was assessed in HEL clones before (uninduced) and after induc-
tion to erythroid differentiation (induced) (Table S1). HEL cells are
capable of both spontaneous and induced globin expression and,
thus, are often used as an erythroid model system.38 b-Globin chains
are absent, and this pattern of globin synthesis is observed after
4–5 days of induction by hemin. To determine individual deregulated
genes in association with viral ISs, the Z score test with an adj.
p < 0.001 was employed. There were no differences in the frequency
of the deregulated target genes among all LVs observed. In uninduced
clones, there were 4, 6, and 1 deregulated genes associated with
viral integration of GLOBE, GATA-GLOBE, and cHS4 LVs, respec-
tively (Figure S1D; Table S1). In induced clones, there were 6, 1,
and 6 deregulated genes associated with viral integration of GLOBE,
GATA-GLOBE, and cHS4 LVs, respectively (Figure S1E; Table S1).
Considering that there are no significant advantages of the newly
derived vectors and given the long development and deep character-
ization of the GLOBE LV,22 we elected to continue the safety charac-
terization with GLOBE LV.
GLOBE LV-Transduced Cells Correct Thalassemia in the Murine
Model
To evaluate the effect of GLOBE LV transduction on hematopoietic
cells in vivo, we designed and performed a bone marrow (BM) trans-
plantation study in a mouse model of b-thalassemia (th3/+ strain, in
compliance with OECD principles and GLP (Figure 1A). The GLOBE
LV batch used in this study was produced at medium scale and
purified by MolMed with a titer of 9.69  107 transduction units
(TU)/mL. Lin cells from th3/+ mice were MOCK-transduced
(th3/+ MOCK) or transduced with GLOBE LV (th3/+ GLOBE LV)
at an MOI of 100 and transplanted into female and male recipient
th3/+ mice (n = 30 per group), which were monitored for up to
12 months after gene therapy. An age-matched untreated control
group was included in the study (th3/+, n = 30).
The transduction protocol was designed to achieve a high VCN supe-
rior to that expected in human cells (VCN R 2). The transduction
efficiency was 100%, and the mean VCN in liquid culture and col-
ony-forming units (CFUs) ranged from 6.03 to 9.69 (number of
experiments = 3) (Table S2A).
Recipient mice were pre-treated with a myeloablative dose of
busulfan, an alkylating agent causing myeloablation to favor the
engraftment of donor cells in recipient HSCs, and transplanted
with 0.4  105 th3/+ Lin cells/mouse, equivalent to approximately
25  106 human CD34+ cells/kg.
Donor and recipient hematopoietic cells were derived from two co-
isogenic strains and could be distinguished by alternative expression
of the allelic form of the pan-leukocyte surface marker CD45, being
CD45.1+ and CD45.2+, respectively, and detected by cytofluorimetric
analysis. Engraftment of th3/+ GLOBE LV cells and th3/+ MOCK12 Molecular Therapy: Methods & Clinical Development Vol. 11 Decemcells was evaluated 16 weeks after transplantation and at termination
in peripheral blood (PB). Overall, engraftment percentages (mean ±
SD) did not significantly change in th3/+ GLOBE LV mice (70.78 ±
26.47 at 16 weeks) versus th3/+ MOCK mice (56.93 ± 39.56 at
16 weeks) (Tables S2B and S2C) and were maintained over time
(67.78 ± 32.85 to 58.14 ± 42.20, respectively) (Figures 1B and 1C;
Tables S2B and S2C). The difference in engraftment percentages
between female and male, observed in the th3/+ GLOBE LV group
(82.71 ± 16.01 male versus 58.87 ± 29.83 female at 16 weeks;
83.64 ± 17.92 male versus 51.93 ± 37.16 female at termination) was
not vector-related because it was also present in th3/+ MOCK mice
(Figure 1B). The immunophenotype analysis of blood nucleated
cells for the percentage of cells expressing B, T lymphoid, and
myeloid-specific surface markers (B220, CD3, and CD11b, respec-
tively) showed a normal pattern of lineage development and no
evidence of abnormal expansion (Figure 1C). High VCN (mean ±
SD) was detected in PB at 16 weeks (6.686 ± 0.8421 male; 4.535 ±
1.060 female) and in BM cells at termination (6.224 ± 0.9259 male;
3.868 ± 1.576 female), demonstrating sustained long-term engraft-
ment of gene-modified cells (Figure 1C; Table S2B). No statistical
difference in VCN was observed between the genders. Overall, these
data indicate that transduced cells were able to engraft at a high level
with no alteration in the hematopoietic reconstitution.
Transplantation of GLOBE-transduced HSPCs in themousemodel of
b-thalassemia showed treatment-related efficacy in terms of rescue of
anemia, with increased hemoglobin levels, RBCs, hematocrit (HCT),
and amelioration of RBC-related parameters (mean corpuscular vol-
ume [MCV], mean corpuscular hemoglobin [MCH], and MCH con-
centration [MCHC]) (Tables S3A–S3C). A low RBC mass level (RBC
count, hemoglobin [HGB], and HCT), consistent with clinical anemia
present in th3/+ mice, was observed in control groups (th3/+ MOCK
and th3/+ mice) (Tables S3B and S3C; Figure 1E). In contrast, th3/+
mice, receiving GLOBE LV gene therapy, showed an increase in RBC
mass levels toward normal circulating levels at both sampling times,
indicating a treatment-related response (Table S3A; data not shown).
The mean RBC count was 6.4–6.8  106/mm3 in control groups and
8.5–9.3 106/mm3 in th3/+ GLOBE LV mice and a mean HGB from
8.7–9.7 g/dL to 12.3–13.3 g/dL and mean HCT from 25.0%–28.7%
to 35.8%–40.5% (Table S3A; Figure 1E). A correlation between per-
centages of transduced engrafted cells and transgene expression,
measured by hematological analysis (HGB), was observed in most
of the cases (Figures 1A, 1D, and 1E). Because VCN analysis is per-
formed on nucleated blood and BM cells, and CD45+ expression is ab-
sent in the erythroid lineage, in a few cases, a therapeutic level of
transgene expression in the presence of a low frequency of transduced
cells and/or low VCNwas detected as a consequence of positive selec-
tion of corrected erythroid cells over the untransduced ones. As in a
previous study,26 correction of hematological parameters was
achieved even in mice with a frequency of BM-transduced cells of
less than 15%, presumably because of positive selection of erythroid
progenitors carrying productive LV integrations. The differences in
all hematological parameters in gene therapy-treated mice versus
those in control groups were statistically significant (GLOBE LVber 2018
Table 1. Incidence of Tumors Observed in Both Decedents and/or Pre-terminally Sacrificed Animals and at Termination
Males Females
Group (n = 15/sex) th3/+ GLOBE LV th3/+ MOCK th3/+ th3/+ GLOBE LV th3/+ MOCK th3/+
Lymphoma (various organs) 1 (ICD) 0 3 (TK) 2 (ICD +TK) 2 (ICD+ TK) 2 (TK)
Histiocytic sarcoma (various organs) 1 0 0 0 0 0
Sex cord stromal tumor in the ovary 0 0 0 1 (TK) 0 0
Bronchiolo-alveolar adenoma in the lungs 0 0 0 0 0 1 (TK)
Sarcoma (not otherwise specified) abdominal 0 1 (ICD) 0 1 (ICD) 0 0
ICD, intercurrent death (days after transplantation); TK, terminal kill sacrificed at 50 ± 1 week.
www.moleculartherapy.orgversus th3/+ MOCK and GLOBE LV versus th3/+, p < 0.0001), indi-
cating correction of disease-related abnormalities provided by the
gene therapy treatment. Increased hemoglobin levels compared
with control groups were observed in all mice at both time points
(16 weeks and 12 months after treatment), with the exception of
animals 952 and 620 at termination, which also showed a low percent-
age of transduced cells (Figure 1E; Table S3A). Interestingly, in th3/+
MOCK and untreated mice, extramedullary hematopoiesis (EMH) is
present in the spleen and liver, with occurrence of related pigmented
macrophages or Kupffer cells. In comparison with both aforemen-
tioned groups, histological analysis of mice transplanted with GLOBE
LV-transduced Lin HSPCs showed a reduction of these cells
(Figure S2).
Evaluation of Toxicity and Tumorigenic Potential of GLOBE LV-
Transduced Murine HSCs
To assess the potential toxicity and/or tumorigenicity of the trans-
plantation of GLOBE LV-transduced cells, mortality and clinical
signs were monitored during the 12-month observation period; clin-
ical chemistry, hematologic parameters, necropsy, and full micro-
scopic examination were performed at termination. A board-certified
pathologist performed the microscopic examination of a full list of or-
gans of all animals. A peer review of the histopathological analysis was
carried out by a second board-certified pathologist.
Differences in survival among the groups were not statistically signif-
icant (Figure 1F). No mortality related to the transplantation proced-
ure of Lin HSPCs transduced with GLOBE LV or MOCK-trans-
duced were observed in the first 4 weeks after treatment. Mortality
was observed in the th3/+ GLOBE LV and th3/+ MOCK groups
from day 154 onward. There were 7 premature decedents, 5 from
the th3/+ GLOBE LV group and 2 from the th3/+ MOCK group (Fig-
ure 1F). Deaths were associated with generalized lymphoma in 2 an-
imals in the th3/+ GLOBE LV group and in 1 animal in the th3/+
MOCK group (Tables 1 and 2). Only in one instance was the cause
of death unknown.
Abdominal sarcomas in 1 animal in the th3/+ GLOBE LV group and
1 animal in th3/+ MOCK group as well (Table 1) were considered to
be related to the intraperitoneal injection of busulfan in an acetone
and peanut oil solution and secondary to the local inflammationMolecular Thinduced by the irritation.39,40 In another case, abnormal dental
growth was the likely cause of decreased food intake, resulting in
premature death in the th3/+ GLOBE LV group. No mortality was
observed in the untreated th3/+ control group (Figure 1F).
Some tumors were recorded throughout all groups with no difference
in tumor incidence or type between the groups, and they were all
considered within the normal background incidence in th3/+ mice
of this age (Table 1). No signs of toxicity and tumorigenicity related
to transplantation of GLOBE LV transduced cells were observed.
Clinical chemistry parameters were evaluated at termination in all
groups to detect potential toxic effects in the liver, kidney, pancreas,
gut, and cardio-circulatory system. No signs of toxicity were found,
and no difference was detected between the three groups in any
parameter (Figure S3).
Hematopoietic Reconstitution in Gene Therapy-Treated Mice Is
Highly Polyclonal and Dynamic
To assess the potential genotoxicity of the GLOBE LV and to analyze
the clonal dynamics of hematopoietic repopulation in the trans-
planted mice, we performed a molecular analysis by retrieving the
vector genomic integrations in PB- and BM-derived cells 16 weeks
and 1 year after transplantation, respectively. We also analyzed the
in vitro products, both liquid culture and CFUs, 10 days after
transduction.
Vector-genome junctions were retrieved by means of linear amplifi-
cation-mediated PCR (LAM-PCR) by using three different restriction
enzymes, as described previously.3,4 To identify the vector ISs, the
sequences of the PCR products generated by MiSeq Illumina
sequencing were mapped on the mouse genome by a dedicated bioin-
formatics pipeline.41 Overall, we mapped 1,673 ISs from in vitro
cultures, 3,080 from PB (at 16 weeks), and 1,738 BM cells (at
12 weeks). Tables S2A and S2B summarize the number of ISs
identified for each sample. For the next set of biological analyses,
we applied a threshold for the minimum number of reads for each
IS (n = 3) with the goal to minimize the number of false positives.
To study the clonal dynamics of the transduced cells during the
hematopoietic reconstitution, we evaluated the sharing degree of
ISs between the PB at 16 weeks and BM 1 year after transplantationerapy: Methods & Clinical Development Vol. 11 December 2018 13
Table 2. Distribution of Hemolymphoproliferative Neoplasia in Both Decedents and/or Pre-terminally Sacrificed Animals and at Termination
Group (n = 15)
Animal Number




617 F ICD (154) lymphoma systemic 12.92 (16.53) 8.69 67.3
690 M ICD (181) lymphoma systemic 15.87 (NA) 7.82 80.9
627 F TK lymphoma systemic 6.2 (0.14) NA 12.8
605 M TK histiocytic sarcoma systemic 7.44 (10.87) NA 88.1
th3/+ MOCK
654 F ICD (260) lymphoma systemic – – 62.2
647 F TK lymphoma lung – – 0.2
th3/+
661 M TK lymphoma mesenteric lymph node – – –
664 M TK lymphoma Peyer’s patch jejunum – – –
665 M TK lymphoma mesenteric lymph node – – –
677 F TK lymphoma Peyer’s patch ileum – – –
689 F TK lymphoma liver – – –
ICD, intercurrent death (days after transplantation); TK, terminal kill sacrificed at 50 ± 1 week; NA, not available; F, female; M, male; –, not applicable.
aPercent chimerism in PB at the latest time point.
Molecular Therapy: Methods & Clinical Developmentand found that 30% of PB ISs were shared with the ISs in BM, indi-
cating self-renewal and multilineage potential of the transduced
engrafted HSPCs (Figure 2A).
Moreover, to quantify clonal diversity over time, we calculated
the Shannon diversity index. This index measures the entropy of
an IS dataset, taking into account the total number of ISs and
their relative contribution. The diversity of ISs in BM 12 months
after transplantation was lower compared with that of PB at 4 months
in almost all sample analyzed, suggesting that a diverse clonal
repertoire is established after transplantation with different active
gene-corrected long-term (LT)-HSC contributing to hematopoiesis
(Figure 2B).
To better investigate this aspect, we measured the proportion of
sequencing reads representing each IS within our datasets as a surro-
gate readout for the relative abundance of a cell clone harboring that
integration at a given time. In PB at 16 weeks, this analysis identified
1–2 clones in 70% of the analyzed mice with a relative abundance
above 10%, a threshold arbitrarily set for defining dominant clones
(Figure S4A). Only one mouse (952) harbored 2 integrations above
30% (Figure S4A). Thus, PB at 16 weeks showed a highly polyclonal
reconstitution pattern.
At termination, in the BM, we found a less polyclonal pattern, with all
mice harboring at least one clone with relative abundance above 10%
(Figure S4B). Mouse 627 was of particular interest because we
retrieved only 2 ISs, and one of them (targeting the Wdr78 gene)
has a relative abundance of 99% in the BM, whereas it was at a very
low level in PB at 16 weeks (Figure S4). The engraftment and VCN
in this mouse were very low at both time points (Table S2B), indi-
cating that few transduced clones are participating to host recovered
hematopoiesis at low levels (Figures 2C and 2D). Furthermore, almost
every cell clone marked by a specific IS accounted for only a fraction14 Molecular Therapy: Methods & Clinical Development Vol. 11 Decemof a percentage of the total hematopoietic clones at any given time
(Figures 2C and 2D).
We also analyzed the genomic distribution of ISs and the gene classes
preferentially hit by LV integration. The genomic distribution of ISs,
both in the in vitro-cultured Lin cells and in vivo, matched the pre-
viously reported LV preference for integration within transcriptional
units (on average, 80% of ISs were within genes).42 In all groups,
z80% of ISs were found between 5 and 500 kb from transcription
start sites (Figures S5A–S5C). From these analyses, it is evident that
the hematopoietic reconstitution of the mice transplanted with trans-
duced cells is highly polyclonal and dynamic and that GLOBE LV
shows the classical integration pattern characteristic of HIV-1-
derived vectors.
To assess to which groups of biological processes genes with inte-
grated vector belong, gene ontology (GO) enrichment analysis was
performed. Interestingly, in in vivo data, we observed an enrichment
in categories belonging to metabolic and biosynthetic processes (Fig-
ures 3A and 3B).
Development of Lymphoproliferative Tumors Occurred
Independently from GLOBE LV Integration
To better define the biosafety of GLOBE LV, we completed IS analysis
mapping in the infiltrated spleens of the two mice dead from lym-
phoma (617 and 690; Table 2). No differences in genomic distribution
were detected with respect to the other IS groups analyzed (in vitro,
PB, and BM) (Figure S5D), and GO (GO) analysis did not identify
enrichment in terms belonging to cancer, abnormal proliferation,
or similar, but it identified a significant over-representation of the sex-
ual development categories (Figure 4A). In these mice, VCN analysis
in lymphoma-infiltrated spleens showed vector marking at a lower
level compared with the other hematopoietic tissues (Table 2), with
a high donor cell chimerism in the blood (67% and 81%, respectively).ber 2018
Figure 2. Hematopoietic Reconstitution of Gene
Therapy-Treated th3/+ Mice Is Highly Polyclonal and
Dynamic
DNA extracted from in vitro cultures, peripheral blood at
16 weeks, and bone marrow at termination was analyzed
for vector integration. (A) Venn diagram showing the over-
lapping ISs between PB and BM. (B) Shannon diversity
index values (y axis) in in vitro samples, PB, and BM. (C)
Histograms of the percentage of sequence reads (y axis) for
unequivocally mapped ISs from PB. The number of reads
for each IS is normalized to the total number of sequence
reads from the same time point and for the engraftment
level. ISs below 1% were collapsed and are shown in gray.
(D) ISs in BM.
www.moleculartherapy.orgHemolymphoproliferative neoplasia was identified in two other
mice (605 with histiocytic sarcoma and 627 with lymphoma) at
termination.
Animal 617 was found dead and showed enlargement and discolor-
ation of the spleen, thymus, mesenteric lymph nodes, and kidney.
Samples of the spleen and thymus were frozen, and IHC was per-
formed. A severe infiltration of atypical enlarged cells involving red
and white pulp was seen. Infiltrating cells were positive for staining
with anti-Ki67, CD3, and CD45.1 antibodies, suggesting a T origin
of the lymphoma cells from donor-derived cells (data not shown).
In the spleen of mouse 617, we identified one clone with a relative
abundance of 48.8% (Figure S6). This IS was also retrieved in theMolecular Therapy: Methods & CBM at a higher relative abundance level (56.4%),
whereas, at an earlier time point, it was at a very
low level (2.8%) (Figure S6). Considering the
correction for engraftment level, this clone ac-
counted for 32.8%–37.9% of total hematopoiesis.
The integration targeting a gene (Klra21) is not
cancer-related; thus, it indicates that the tumor
is marked by a neutral integration. Similar results
were obtained in mouse 690, where we identified
two ISs with a relative abundance of 25.5% and
21.7% that, considering the engraftment level,
accounted for the z20% of total hematopoiesis
(Figure 4B). Comparing these results with those
in tumor-free mice, the clonal expansion was
not relevant for cancer development (Figure 4B).
Moreover, mice bearing hemolymphoprolifera-
tive tumors recorded at termination (605 and
627) showed dominant clones with lower abun-
dance (z12% in BM), whereas tumor-free mice
had clones with a similar or higher abundance
(z37% in BM) (Figure 4B).
Then, we performed an analysis of cancer-asso-
ciated genes using the Retroviral Tagged Can-
cer Gene Database (RTCGD) database. In all
four samples (in vitro, BM, PB, and SP sam-ples), z20% of genes are present in the database (Table S4).
From the analysis of tumors, we did not see any enrichment in
the abundance of integrations targeting cancer genes, suggesting
that the integrations are not involved in the transformation
process.
To determine whether other hallmarks of insertional mutagenesis
were present in the GLOBE LV integration profile, we assessed the
occurrence of common ISs (CISs), insertional hotspots that may
result from integration bias at the time of transduction or in vivo
selection of clones harboring integrations that confer a growth advan-
tage. CISs were identified with an algorithm based on Abel et al.43 and
by the Grubbs test for outliers.34 CIS analysis did not show anylinical Development Vol. 11 December 2018 15
Figure 3. Gene Ontology Analysis of ISs
Gene ontology (GO) analysis was performed using the GREAT
software on in vitro cultures, peripheral blood at 16 weeks, and
bone marrow at termination at 12 weeks. The integrations
retrieved from each group showed overrepresentations of the
gene functions indicated on the left. Only gene classes with a false
discovery rate of less than 0.05 were considered. We interrogated
the Biological Process database in (A) peripheral blood and
(B) bone marrow.
Molecular Therapy: Methods & Clinical Developmentalarming sign of genotoxicity because the only significant CIS
was found in the control dataset of in vitro-cultured cells. A less
stringent correction of the p values obtained in our CIS analysis
also allows finding “weaker” CISs in the integration datasets in vivo
(PB and BM). Interestingly, the CISs found in BM 1 year after
transplant are less and are targeted by fewer integrations than the
CIS identified in PB 16 weeks after transplantation. Thus, even a
less stringent correction of the CIS significance does not show any
abnormal enrichment of CISs over time. Moreover, CISs were not
represented by high sequence counts and did not preferentially target
oncogenes.
Overall, these analyses showed a safe integration profile of GLOBE LV
in murine HSC and that GLOBE LV is not directly linked to tumor
development.
Human CD34+ Cells Transduced with GLOBE LV Are Able to
Engraft and Reconstitute NSG Mice
As a further step, we assessed whether the distribution of GLOBE
genetically modified human CD34+ cells in the organs of the immu-
nocompromised NSG mouse model was comparable with that of
unmodified cells. We tested GLOBE LV-transduced human CD34+
cells for their ability to engraft, differentiate into lineage-specific
progeny, and localize into lympho-hematopoietic murine tissues.
Cord blood-derived CD34+ cells (UCB-CD34+) were transduced with
a GLOBE LV batch manufactured under good manufacturing prac-
tice (GMP) conditions. Transduced (CD34 GLOBE LV) or MOCK-
transduced (CD34 MOCK) cells were injected intravenously (i.v.)
into sub-lethally irradiated NSG mice (CD34 GLOBE LV, n = 12;
CD34 MOCK, n = 12). A third group of age-matched mice was
included in the study as an untreated control group (CD34 Ctrl,
n = 6). The mice were monitored daily for survival and weekly for16 Molecular Therapy: Methods & Clinical Development Vol. 11 December 2018clinical signs and body weight until 12 weeks after
transplantation. At the end of the study, the engraft-
ment, differentiation to specific lineages, and persis-
tence of transduced human cells in hematopoietic or-
gans (blood, BM, spleen, and thymus) were assessed.
After extensive perfusion to reduce contaminating
blood, gonads and brain were analyzed by qPCR to
evaluate the distribution of human cells also in non-
hematopoietic off-target organs (Figure 5A). There
were no clinical signs considered to be related to thetreatment and no mortality was observed during the study up to
termination, except for one mouse in the CD34 MOCK group that
died after bleeding at 11 weeks (day 77).
The immunophenotype analysis data showed successful and robust
engraftment of transduced and MOCK-transduced UCB-CD34+ cells
in NSG mice after sub-lethal irradiation. Statistical analysis showed a
lower percentage of human CD45+ cells detected in the periphery in
CD34 GLOBE LV mice (mean ± SD, 13.96 ± 3.146) compared with
CD34 MOCK mice (31.24 ± 4.83) (p = 0.0066); however, no differ-
ence was found in the BM (25.23 ± 2.28 versus 33.40 ± 4.22) and
in the spleen (17.86 ± 4.34 versus 12.56 ± 7.23) (Figure 5B). As
expected, in the NSG model,44 the higher proportion of human cells
was represented by B cells (CD19+ cells) in the PB and in the hemato-
poietic organs (Figures 5C–5E). The BM showed human HSPC
engraftment (immunostaining with anti-human CD34) with multi-
lineage differentiation of lymphoid and myeloid cells (immunostain-
ing with anti-human CD19, CD3, and CD11b). No significant differ-
ences in CD34+ levels were observed between groups in the BM,
indicating a comparable capacity of CD34 GLOBE LV cells (3.25 ±
0.50) and CD34 MOCK cells (4.76 ± 0.66) to engraft and reconstitute
in vivo (Figure 5D).
No differences in VCN were observed among the target organs PB,
BM, and SP (4.04 ± 1.59, 5.09 ± 2.97, and 4.38 ± 1.03, respectively)
(Figure 5F). The average VCN measured in all examined hematopoi-
etic tissue was comparable with the VCN measured in the bulk pop-
ulation of the transduced cells prior to administration (4.11).
At termination, non-hematopoietic organs (ovaries and brain) were
collected from NSGmice after perfusion to assess the risk of germline
transmission through vector shedding and secondary transduction
or inadvertently generated replication-competent lentivirus (RCL).
Figure 4. Gene Ontology Analysis and Abundance Analysis of ISs from Infiltrated Tumors
DNA extracted from infiltrated tumor spleens was analyzed for vector integration (mice 617 and 690). (A) GO analysis was performed using the GREAT software. The
integrations retrieved from tumors showed overrepresentations of the gene functions indicated on the left. Only gene classes with a false discovery rate of less than 0.05 were
considered. We interrogated the Biological Process database. (B) Histograms of the percentage of sequence reads (y axis) for unequivocally mapped ISs from mice that
developed lymphomas and hemolymphoproliferative neoplasia and healthy controls. The number of reads for each IS was normalized to the total number of sequence reads
from the same time point and for the engraftment level. ISs below 1% were collapsed and are shown in gray.
www.moleculartherapy.orgThe ovaries of 10 of 12 mice in the CD34 GLOBE LV group were
negative or below the LOQ (low limit of quantification) for VCN
analysis (Figure 5G). In the ovaries of the other 2 mice, less than
0.5% of human cells were detected. The VCN of 12.26 in the ovary
sample from mouse 1-05 was generated by a ratio between low LVMolecular Thcopies and an amount of human DNA very close to the LOQ. The
brains of 11 of 12mice were negative or below the LOQ for VCN anal-
ysis (Figure 5G). The VCN of 3.60 in mouse 1-11 was below the PB
VCN of the same mouse (6.43). These data are likely were likely
caused by false positives or related to incomplete perfusion so thaterapy: Methods & Clinical Development Vol. 11 December 2018 17
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www.moleculartherapy.orgresidual blood containing high VCNs can be measured in these sam-
ples, as shown in Visigalli et al.45 Calculation of VCN in mouse
tissues, as a ratio between murine genomes (b-actin target ng) and
LV genomes (HIV ng), excluded the association of LV with murine
cells (data not shown). Occasionally, a low signal for vector DNA
was detected in non-target organs of control group mice, setting the
background threshold of sample processing and the qPCR procedure.
Serum samples from CD34 GLOBE LV mice (1-01, 1-02, 1-05, 1-08,
and 1-09) that showed a low level of LV DNA in ovary and/or brain
in the presence of low or undetectable levels of human DNA (hTELO
ng) were also analyzed by HIV p24 assay to exclude the presence
of circulating aberrantly generated RCL. All analyzed samples were
negative in the HIV p24 detection assay; i.e., below the analytical
sensitivity of the ELISA test (<3.125 pg/mL).
Overall, these results showed that the GLOBE medicinal product suc-
cessfully engrafts and differentiates into the myeloid and lymphoid
progeny at a level comparable with that observed for MOCK-trans-
duced CD34+ cells. Notably, the proportion of human cells retaining
the primitive CD45+/CD34+ phenotype was comparable in mice
receiving GLOBE LV-transduced and MOCK-transduced cells. No
evidence of LV transfer in non-target organs, gonads and brain,
was found.
In Vitro and Ex Vivo ISs Profiles of GLOBE LV in Human CD34+
Cells
The GLOBE LV integration profile was determined by LM-PCR
coupled to high-throughput sequencing in vitro in the pool of trans-
duced human CD34+ cells before transplantation and ex vivo in the
BM of the 10 transplanted NSG mice at the end of the study. All
mice were injected with 0.5  106 transduced CD34+ cells, with a
resulting chimerism of 20%–35% human cells and a VCN ranging
from 1 to 10 (Figure 6A). Overall, 14,023 unique LV ISs were retrieved
in the transduced CD34+ cells and 2,518 ISs in the pool of trans-
planted mice at the end of the study, indicating a highly polyclonal
BM repopulation. The LV integration profile was also determined
in individual animals, retrieving an average of 354 ISs/mouse (range,
146–709 ISs; SD = 183; Table S5).
Overall, no or few dominant clones (i.e., accounting for 10% or more
of the total reads) were evidenced in post-transplant libraries by
analyzing the final ISs read count (Figure 6B). In single-mouseFigure 5. Biodistribution Study in the Human Chimera Murine Model
(A) Experimental plan of the biodistribution study. Female NSG (NOD.Cg-Prkdcsid Il2rg
provide depletion of endogenous BM cells, allowing engraftment of human cells. Af
transduced CD34+ cells, NSGMOCKmice (n = 12) were treated with MOCK-transduced
end of the study, the engraftment, the differentiation to specific lineages, and the pers
extensive perfusion to eliminate contaminating blood, gonads and brain were analyzed b
p24 was assayed in mouse serum to test for the absence of replication-competent lent
analysis in PB, BM, and SP by using anti-human CD45+ (**p < 0.01, two-tailed Studen
lymphoid and myeloid cells (CD19+, CD3+, and CD13+) both in transduced and MOCK
qPCR. (G) VCN per cell was determined in ovaries and brain. All values are shown as m
Molecular Thlibraries, most of the ISs had a read count of lower than 1% (low
frequency, shown in gray in Figure 6B), whereas a variable number
of ISs (6–22) had a relatively higher frequency (more than 1%, colored
boxes in Figure 6Bb), most likely reflecting the limited number of
long-term repopulating hematopoietic stem cells in the transplanted
BM. Altogether, ISs with a read count of more than 1% in any
individual animal targeted 128 genes, which were not significantly
enriched for any biological function by GO Database for Annotation,
Visualization and Integrated Discovery (DAVID) analysis (data not
shown). Interestingly, none of these ISs was found to be in common
among the different animals.
The relative distribution of ISs inside and outside of genes changed
in the post-transplant samples with respect to pre-transplant-trans-
duced CD34+, with a significant increase in the fraction of intergenic
ISs (c2 test p < 0.0001). This effect was particularly evident in two
of ten mice analyzed (TM024-1-01 and TM024-1-05; Table S5;
Figure S8).
Overall, we retrieved 4,802 and 1,316 genes targeted by LV GLOBE in
pre-transplant CD34+ cells and post-transplant BM, respectively. The
number of targeted genes was positively correlated with the number
of ISs (Figure S7A), with most of the targeted genes hosting 1 provirus
(data not shown), ranging from 1–50 ISs/gene in pre-transplant
CD34+ cells (50 ISs in PACS1, all low-frequency ISs), 1–12 ISs/gene
in merged BM samples (12 ISs in LOC440434, all low-frequency
ISs), and 1–9 ISs in individual mice. Among the top 100 genes tar-
geted ex vivo, we found genes preferentially targeted by LVs, such
as PACS1, KDM2A, and others, as observed in the pre-transplant
CD34+ cells (Figure S7C) and in three LV-based clinical trials.3,46
The genes targeted in pre-transplant CD34+ cells were significantly
enriched in several biological functions (Figure S7D). Targeted genes
in post-transplant BM were not significantly enriched in any GO bio-
logical function category or molecular pathway (Kyoto Encyclopedia
of Genes and Genomes [KEGG] pathways dataset) with respect to the
pre-transplant sample by DAVID analysis (data not shown), suggest-
ing no selection for clones carrying LV integration in genes involved
in particular functions. Although most of the targeted genes were in
common in post- versus pre-transplant cells (Table S6), only 1 or 2
individual ISs were shared between pre- and post-transplant samples
(Figure 6C; Table S7). On the contrary, several ISs were shared among
individual mice (Figure 6C; Table S7), ranging from 8% to 64% of the
total ISs (Figure S8).tm1Wjl/SzJ) recipient mice were conditioned by a sub-lethal dose of irradiation to
ter conditioning, NSG GLOBE LV mice (n = 12) were intravenously injected with
cells, and NSG control mice (n = 6) were left untreated and served as controls. At the
istence of transduced human cells in hematopoietic organs were evaluated. After
y qPCR to evaluate the distribution of human cells in non-hematopoietic organs. HIV
ivirus. (B) Analysis of hematological reconstitution was assessed by cytofluorimetric
t’s t test ). (C–E) PB (C), BM (D), and SP (E) showed multi-lineage differentiation of
-transduced cells. (F) VCN per cell was determined in PB, BM, SP, and thymus by
ean ± SD.
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Here we analyzed transgene expression and production from three
different globin LVs, specifically GLOBE, GATA-GLOBE, and
cHS4-GLOBE, and their potential deregulation of cellular genes
located in the vicinity of or containing the vector insertion in human
cells. No significant differences were observed among LVs. On the
basis of these experiments and given the long development and
deep characterization of the GLOBE LV,22 we decided to continue
the safety characterization with GLOBE LV.
We observed that GATA-GLOBE LV produced more b-globin tran-
script than GLOBE LV. This higher transcription activity is due the
presence of the GATA1-HS2 element in the LV, which binds the tran-
scription factors CP2 and BCL11A.47,48 Our data confirmed the
potential GATA1-HS2 anti-silencing effect.37 However, this tran-
scriptional difference was not confirmed at the protein level. More-
over, evaluation of the perturbation of genes hit by LV integration
highlights that GLOBE LV deregulated gene expression with a fre-
quency similar to the other b-globin-expressing LVs reported in
this paper and in the literature.18–20 Hargrove et al.20 showed that vec-
tor integration perturbed the expression of genes with a frequency
of 11%, whereas GLOBE LV showed a frequency of 4% and 7% in
immature and more mature erythroid cells, respectively (Table S1).
The safety and efficacy of GLOBE LVwere tested in vivo by transplan-
tation experiments following the guidelines for GLP in the GLP-SR-
Tiget test facility. The preclinical study for gene therapy of mucopo-
lysaccharidosis I (MPS I), recently published by Visigalli et al.,45 was
performed in this facility following the same guidelines. We designed
an in vivo study aimed to evaluate the safety and efficacy of GLOBE
LV in a mouse model of b-thalassemia intermedia (th3/+). Engraft-
ment and transduction were very efficient, and the thalassemic
phenotype was fully corrected in all mice, with two exceptions (620
and 952). Mouse 620 had very low engraftment (5.4%). Mouse 952
had an engraftment of 11.5% with a VCN in the marked cells of
1.39 (VCN 0.16 on total BM) and themost abundant clone, represent-
ing about 5% of total hematopoiesis. However, 2 mice with similar
abundant clones were fully corrected with similar VCN in the marked
cells (1.88–1.43). These data suggest that, in the presence of genomic
low VCN per cell, the transcriptional activity of the vector might be
influenced by surrounding chromatin.49 Interestingly, GLOBE LV
corrects the thalassemia phenotype with 1 copy present in about
10% of total hematopoietic cells, as shown by mouse 627, confirming
previously published data.26
VCN per-cell values were lower and with a higher variability in the
female groups, a reflection of variability in engraftment level. ThisFigure 6. In Vitro and Ex Vivo Integration Site Analysis of LV GLOBE in Human
(A) Human versus mouse chimerism and VCN evaluation in the BM of transplanted NSG
transplant transduced CB CD34+ cells and in the different BMs of transplanted mice at t
trimmed reads, whereas the other colors indicate a read count higher than 1%. ID numbe
than 1% were shared among the individual transplanted mice. (C) Shown on the left and
samples, including or not including the pre-transplant CB CD34+ cells.
Molecular Thfinding was not vector-related because it also occurred at a higher
level in the control group (th3/+ MOCK mice). Variability of
engraftment might be expected because of variable bioavailability of
busulfan. Pharmacokinetic studies have verified great inter-patient
variations because of age, circadian rhythmicity, and underlying dis-
eases.50–53 As an additional factor to this variability, a gender-related
different liver metabolism, influencing drug clearance in the th3/+
strain, which is characterized by hepatic iron imbalance, can be
hypothesized. A higher liver iron concentration in th3/+ females54
and a testosterone-related effect on iron homeostasis might influence
metabolic liver function. Because dose adjustment, based on busulfan
plasmatic dosage, is not feasible in mice, variable drug effects might
have occurred, and a partial level of myeloablation because of biolog-
ical variability and different sensitivity to busulfan treatment in
females compared with males might have affected the level of engraft-
ment of transplanted cells. Histopathological evaluation of tissues,
clinical chemistry, and hematology did not reveal any vector-related
safety concerns.
In the gene therapy-treated group, we reported 2 premature deaths
because of generalized lymphoma and 2 mice with lymphoma and
histiocytic sarcoma at terminal sacrifice. To understand whether these
tumors could have been induced by insertional mutagenesis, the
average VCN per cell was assessed in the spleens of premature dece-
dent animals (617 and 690). These animals showed high donor cell
chimerism (67% and 81%) and vector marking (12.92 and 15.87) in
the blood but a lower VCN (z2-fold) in the affected tissues
(8.69 and 7.82). Moreover, because these malignancies were also pre-
sent in the MOCK group (1 premature death and 1 terminal kill) and
in the untreated group (5 terminal kills), they are not considered a
treatment-related finding. A total of 8,362,036 sequence reads re-
sulted from the appropriate data filtering process of the original reads.
The relative abundance of sequences representing each IS (a clonal
mark) with respect to the total number of sequences provided an
estimation of the relative abundance of a cell clone in the transduced
population. The highest estimated values of the abundance of individ-
ual cell clones at early (16 weeks) or late (at termination) time points
after transplant was lower than 4% of the entire dataset, which is
below the threshold value generally associated with clonal domi-
nance.3,4 To complete the safety profile of GLOBE LV treatment, IS
analyses were performed on neoplastic tissue, PB, BM, and pre-
transplant samples. As expected, transplantation of a high amount
number of lineage-negative mouse BM cells resulted in a polyclonal
hematopoietic repopulation with preferential insertions (80% of
ISs) in gene coding regions. These ISs do not show evidence of enrich-
ment in growth- or cancer-related genes, and no CISs were retrieved
in in vitro and in vivo samples.HSPCs
mice at the end of the study. (B) Read count distribution per single IS obtained in pre-
he end of the study. The gray color indicates a read count lower than 1% of the total
rs for each IS are indicated in the boxes. In the study, no ISs with a read count greater
right, respectively, are chord diagrams indicating the shared ISs among the different
erapy: Methods & Clinical Development Vol. 11 December 2018 21
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MDS1-EVI1 or LMO2, which were previously linked to malignant
transformation in the gene therapy setting. In fact, integration of
gamma retroviral vectors into these loci has been associated with
tumor development in patients treated for chronic granulomatous
disease55 or X chromosome-linked severe combined immunodefi-
ciency andWiskott Aldrich syndrome.56–58 Together, these data indi-
cate prediction of a safe integration profile of GLOBE LV.
In addition, the tumors we observed are not likely to be driven by
integrations in dangerous genes, and our data are supported by a
number of other studies describing spontaneous lymphomas in aging
mice and undergoing conditioning.29,32,56,59–62 In fact, lymphomas
have been reported to be the most commonly observed spontaneous
tumors62 in C57BL6 mice,61 the background of our disease model.
Moreover, chemicals, retroviruses, or irradiation induces lymphoma
and leukemia.32,63,64 These studies suggest that there are other risk
factors for oncogenesis in hematopoietic gene therapy protocols
besides integration of LVs in the genome. Moreover, our data are
in agreement with the findings of Visigalli et al.45 In conclusion, over-
all phenotype correction of thalassemic mice was observed with
GLOBE LV, with no alteration of BM homeostasis in the transplanted
animals.
Because the experimental medicinal product is represented by human
autologous transduced CD34+ cells, and there is limited clinical expe-
rience with the ex vivo use of LV, we designed assays to assess the bio-
distribution and the potential risk of vector shedding, mobilization,
and germline transmission using the relevant human target cells in
in vivo models. In particular, we assessed whether the distribution
of the GLOBE medicinal product (GLOBE LV genetically modified
human CD34+ cells) in the organs of the humanized mouse model
was comparable with that of unmodified cells. Our results indicate
that the clinical-grade GLOBE LV can transduce, with high efficiency,
human CD34+ progenitors. The two-hits protocol allowed us to reach
4 VCN/cell with no detectable toxic effect on in vivo differentiation of
CD34+ cells. It should be noted that the selected protocol is already
adopted in LV-based trials for genetic diseases where no side effects
have been reported so far.3,4
Our results show that GLOBE LV-transduced HSCs migrate to the
hemolymphopoietic organs and undergo in vivo short-term differen-
tiation, similar to unmodified HSCs. Our data, combined with previ-
ous observations,45 indicate that the use of the immunodeficient
strain NSG, which allows efficient engraftment of human cells, repre-
sents a suitable model for assessing the biodistribution of human
CD34+ cells.33 Our data show that LV distributes along with human
hematopoietic cells, remaining integrated in the human genome, and
is not mobilized or shed to murine cells. In addition, HSPC with the
integrated vector can be detected in several tissues, including germ-
lines. The detection of HIV sequences in the ovaries and/or brain
of 5 mice together with the absence of HIV p24 gag antigen in the
serum excluded the possibility that an RCL may have been generated.
The safety features of the third-generation packaging system com-22 Molecular Therapy: Methods & Clinical Development Vol. 11 Decembined with a SIN transfer vector used in this study make it extremely
unlikely that a productive viral recombinant is generated during vec-
tor production or cell transduction. Thus, the most likely interpreta-
tion of the findings is an incomplete perfusion procedure, so that re-
sidual blood containing high VCNs and human cells also in the
MOCK group can be measured in these mice. As in the murine study,
we performed IS analysis of the infused product to determine the
safety profile of the GLOBE LV medicinal product. The transduced
CD34+ cells showed a high polyclonal pattern of integration with
no expansion or selection of specific ISs. Moreover, the genes prefer-
entially targeted by GLOBE LV were PACS1, KDM2A, and others,
which are well known hotspots in preclinical studies of LVs34,65
and in lentiviral gene therapy trials and have not been associated
with clonal expansion.3,4,46 We were able to detect several ISs shared
among individual mice, suggesting that our transduction protocol
maintains engraftment potential and that hematopoietic primitive
cells remain multipotent and are able to generate new blood cells.
In summary, our data demonstrate that the GMP-grade b-globin
encoding GLOBE LV can efficiently transduce CD34+ cells under
validated clinical conditions with no toxicity. These studies provide
important information about the quality and the safety data of trans-
duced HSCs for thalassemic patients, complementing previous
in vitro and in vivo studies performed in the murine th3/+ model,
which showed efficient engraftment of vector-transduced cells and
immune reconstitution without the occurrence of LV-induced
toxicity and tumorigenicity tumors. Thus, this work strongly supports
the translation of our gene therapy approach to the clinic as a phase
I and II gene therapy clinical protocols based on infusion of GLOBE
LV-transduced autologous CD34+ cells. Our trial received approval




The GLOBE and GATA-GLOBE LVs have been described previ-
ously.26,37 The cHS4-GLOBE LV was generated by cloning a BamHI
1.2-kb fragment containing the HS4 element from the chicken
genome18,66 into SpeI-SfiI sites of the LTR of the GLOBE vector
backbone.26
Research-grade viral vector stocks were prepared by transient co-
transfection of HEK293T cells using a three-plasmid system as
described previously.26
For toxicology and biodistribution studies, we derived the
pCCL.GLOBE Kana LV from the original PRRL GLOBE LV
described previously. The pRRLsincpptW1.6Wasp-WPREmut6-
Kana (a kind gift from L. Naldini) provided the main backbone.
Medium- and large-scale purified vector lots for the GLP studies were
produced by MolMed (Milan, Italy). Vectors were produced by a
medium- or large-scale process based on transient quadri-transfec-
tion in 293T cells, followed by purification through endonucleaseber 2018
www.moleculartherapy.orgtreatment, anion exchange chromatography with gradient elution, gel
filtration, resuspension in serum-free medium, 0.22-mm filtration,
and aseptic filling. Each lot was characterized in terms of titer,
potency, purity, and safety aspects (titer of the vector in the toxicology
study, 9.69  107 TU/mL; titer of the vector in the biodistribution
study, 6.6  108 TU/mL).
Transduction and Culture of Cell Lines
The HEL cell line was purchased from the ECACC (European Collec-
tion of Cell Cultures). HEL cells were grown in RPMI 1640 medium
(Lonza, Basel, Switzerland) supplemented with 10% fetal bovine
serum (FBS) (GE Healthcare Life Science, Little Chalfont, UK),
100 U/mL penicillin and streptomycin, and 2 mM L-glutamine
(Lonza, Basel, Switzerland) and transduced with viral stocks at a
multiplicity of infection (MOI) of 20 in the presence of 8 mg/mL
Polybrene (Sigma-Aldrich, St. Louis, MO).
Terminal erythroid differentiation was obtained by culturing the cells
in the presence of 50 mM hemin (Sigma-Aldrich, St. Louis, MO) for
5 days.
Single cell-derived clones were obtained by limiting dilution in
96-well plates (0.3 cells/well). Clones were screened by vector-specific
PCR.
Southern and Northern Blot Analyses
Genomic DNA was extracted using the QIAamp DNA blood mini
kit (QIAGEN, Hilden, Germany). Ten micrograms of DNA were
digested overnight with AflII, EcoRV, SpeI, XbaI, or KpnI (all from
New England Biolabs, UK), run on a 0.8% agarose gel, transferred
to a nylon membrane (Hybond-N; GE Healthcare Life Science,
Little Chalfont, UK) by Southern capillary transfer, probed with
2  107 dpm of a 32P-labeled HS3 probe, and exposed to X-ray film.
Total cellular RNA was extracted by TRI reagent (Sigma-Aldrich, St.
Louis, MO), size-fractionated on 1% agarose-formaldehyde gel,
blotted onto nylon membranes, hybridized to 107 dpm of 32P-labeled
GATA-1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
probes, and exposed to X-ray film.
Western Blot Analysis
Protein extraction was performed by resuspending cells in lysis buffer
(150 mM NaCl, 1% v/v NP40, 0.5% w/v deoxycholic acid, 0,1% w/v
SDS, and 50 mM Trizma base [pH 7.8]) and centrifuged to remove
cellular debris. Five micrograms of protein were then mixed with
NuPAGE LDS sample buffer and NuPAGE sample-reducing agent
(Invitrogen, Carlsbad, CA), boiled, and separated by SDS-PAGE on
a 10% polyacrylamide gel. After being transferred to nitrocellulose
membranes, the blots were blocked with PBS containing 0.1% Tween
20 and 5% milk for 1 hr at room temperature. The blots were probed
for 1 hr at room temperature with an appropriate dilution of the pri-
mary antibodies. After washing with PBS containing 0.1% Tween 20,
horseradish peroxidase-conjugated anti-mouse immunoglobulin G
(IgG) was applied to the membrane for 1 hr at room temperature.Molecular ThThe signals were then visualized with an enhanced chemilumines-
cence (ECL) kit (GE Healthcare Life Science, Little Chalfont, UK),
and the intensity of the bands was quantified by ImageJ software
(https://imagej.nih.gov/ij/).
Quantitative Analysis of Gene Expression
Total cellular RNA was extracted by TRI reagent (Sigma-Aldrich, St.
Louis, MO), purified using the Purelink RNA mini kit (Invitrogen,
Carlsbad, CA), and treated with DNase I (Sigma-Aldrich, St. Louis,
MO) to remove DNA contaminations. The absence of genomic
DNA was verified by genome-specific PCR. Reverse transcription
was performed using a high-capacity cDNA reverse transcription
kit (Applied Biosystems, Foster City, CA), following the manufac-
turer’s instructions.
Gene expression levels were evaluated on a custom low-density array
card (“Assay on Demand,” Applied Biosystems, Foster City, CA) us-
ing an ABI PRISM 7900HT system. Relative quantification was calcu-
lated using the DCt method.67 DCt was calculated for every gene as
Ct (gene)  average Ct (GAPDH, b2 microglobulin, RPLP0). DDCt was calcu-
lated for test clones as Ct(test) average Ct(controls). The relative quan-
tification (RQ) of each transcript was calculated as 2–DDCt and plotted
as log2 values.
Analysis of VCN
To evaluate the number of LV copies integrated per genome, qPCR
was performed using specific primers and probes for human telome-
rase, murine b-actin, and a LV, as described previously.33 A reference
standard was obtained from serially diluted transduced human T cell
lines carrying one copy of the integrated LV or murine NIH 3T3 cell
line carrying six copies of LV. The results of integrated vector copies
were normalized for the number of evaluated genomes. As a negative
control, samples of untransduced cells were used. All the reactions
were performed according to the manufacturer’s instructions and
analyzed with an ABI PRISM 7900 sequence detection system or
ViiA7 real-time PCR system (Applied Biosystems, Foster City, CA).
GLOBE IS Mapping and Analysis
ISs were cloned by LAM-PCR and LM-PCR.
For LAM-PCR, after linear PCR amplification of genome-vector
junctions, followed by magnetic capture and second strand reconsti-
tution, digestion with Tsp509I, HpyCH4IV, or MseI was performed.
Digestion products were ligated with a restriction site-complemen-
tary linker cassette and underwent two sequential rounds of exponen-
tial PCR steps. The LAM-PCR products were tagged with mega-
primers and underwent next-generation sequencing on the MiSeq
instrument (Illumina). The resulting genomic sequences were auto-
matically aligned to the mouse genome (July 2007 assembly mm9
of the University of California Santa Cruz (UCSC) genome browser;
http://genome.ucsc.edu/).
The relative abundance of ISs was computed from the matrix files
cleaned by contaminations (also called collisions). For each sample,erapy: Methods & Clinical Development Vol. 11 December 2018 23
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the sequence reads over the total reads of the samples. When appli-
cable, abundance was also correct for engraftment as abundance/
engraftment  100.
All GO analyses were made using the Genomic Regions Enrich-
ment of Annotations Tool (GREAT) online software (http://
bejerano.stanford.edu/great/public/html/). We uploaded the
genomic coordinates of the integrations of each dataset and calcu-
lated the enrichment levels in the tested dataset by correlating
positional information (based on the binomial distribution
analysis for p value calculations) and the annotated function of
the genes closest to the ISs (based on the hypergeometric distribu-
tion analysis for p value calculations). Biological processes of
the GO database were chosen for enrichment analysis. Only
gene classes with a false discovery rate of less than 0.05 were
considered.
For LM-PCR, 0.150–500 ng of genomic DNA was digested with
the MseI restriction enzyme (Roche). The digestion products were
purified (NucleoSpin Gel and PCR Clean-up, Macherey-Nagel)
and ligated to a restriction site-complementary double-stranded
DNA linker. The ligation products were purified and digested
with the SacI restriction enzyme (Roche) to avoid amplification of
the internal provirus. Vector-genome junctions were amplified by
LM-PCR, a nested PCR performed with specific primers annealing
on the linker and the 30 viral LTR, containing a 4-bp tag for sample
identification. Finally, LM-PCR libraries were quantified, size-
selected by gel extraction, checked by capillary electrophoresis
(2100 Bioanalyzer Instrument, Agilent Technologies), and tagged
with sample-specific dual indexes and Illumina sequencing adapters
(Nextera XT Index Kit, Illumina) before being sequenced to
saturation on the MiSeq instrument (Illumina). The resulting
genomic sequences were demultiplexed by sample-specific tag and
bioinformatically processed, trimmed by Skewer68 and mapped on
the human genome (February 2009, GRCh37/hg19) by Bowtie2
software.69 During the mapping step, a quality score was assigned
to each insertion site based on the total number of trimmed reads
collapsed in that genomic position (read count) and the mean
read quality. For each sample, the abundance value was obtained
as the percentage of the read count over the total reads of the sam-
ples. DAVID software70 was used for GO analysis LV-targeted genes
(Refseq database), considered as transcriptional units with inside at
least one IS.
Mice, Murine HSPC Transduction, and Transplantation
C57BL/6-Hbbth3 CD45.2 mice were purchased by Jackson Labora-
tory. C57BL/6-Hbbth3 CD45.1 mice were generated in our institute.
We bred C57BL/6 CD45.1 mice to C57BL/6-Hbbth3 CD45.2 mice
and then intercrossed the C57BL/6 Hbbth3 CD45.1/CD45.2 progeny
and C57BL/6 CD45.1 to generate C57BL/6-Hbbth3 CD45.1 mice.
All procedures were performed according to protocols approved by
the Committee for Animal Care and Use of the San Raffaele Scientific
Institute (Committee Protocol 537).24 Molecular Therapy: Methods & Clinical Development Vol. 11 DecemRecipient C57BL/6-Hbbth3 Ly-5.1 mice were treated intraperitoneally
with busulfan (Sigma-Aldrich, St. Louis, MO) at 25 mg/kg/day for
4 days to obtain myeloablation prior to transplantation. Prophylactic
antibacterial therapy was given by administration of gentamycin
sulfate 80 mg/252 mL (0.3 mg/mL) by water intake from day 7 to
day +7. Donor C57BL/6-Hbbth3 mice were killed by CO2 lethal
inhalation, and BM from both tibia and femora was harvested
into Miltenyi Biotec buffer to obtain Lin HSPCs. Lin HSPCs
were purified with a Lineage Cell Depletion Kit Mouse (Miltenyi
Biotec, Auburn, CA), seeded in StemSpan medium (STEMCELL
Technologies, Vancouver, BC, Canada) supplemented with
mIL3 (10 ng/mL), mIL6 (20 ng/mL), mFLT3L (10 ng/mL), and
murine stem cell factor (mSCF; 50 ng/mL) (all from PeproTech,
Rocky Hill, NY). Lin HSPCs were transduced with GLOBE LV at
MOI 100 for 16–18 hr. MOCK-transduced cells were cultured
under the same conditions in the absence of GLOBE LV to prepare
the control item.
Transduced or MOCK-transduced cells were injected (4  105 cells
per mouse) i.v. in 8- to 12-week-old C57BL6/Hbbth3 mice.
In vitro liquid culture of transduced or MOCK-transduced Lin
HSPC progeny was performed to conduct VCN and IS analysis.
1  106 Lin HPSCs were seeded in liquid culture medium supple-
mented with 5% FBS with mIL3 (10 ng/mL), mFLT3L (10 ng/mL),
mIL6 (20 ng/mL), and mSCF (50 ng/mL) (all from PeproTech, Rocky
Hill, NY) and cultured for 12 ± 2 days. 2.5  103 transduced or
MOCK-transduced Lin HPSCs were seeded in methylcellulose
medium (MethoCult M3434; STEMCELL Technologies, Vancouver,
BC, Canada), colonies were scored on day 10 ± 2, and DNA was pre-
pared for VCN analysis.Post-transplant Monitoring
Mortality and morbidity were checked once a day each working day.
Animals were observed individually once a week for the recording of
clinical signs and body weight. Blood samples for hematology ana-
lyses and DNA analyses were collected 16 weeks after transplantation
and at termination. Erythrocyte count, mean cell volume, packed cell
volume, hemoglobin, mean cell hemoglobin concentration, mean cell
hemoglobin, thrombocyte count, leucocyte count, differential white
cell count with cell morphology, and reticulocyte count were deter-
mined using the Scil Vet ABC Plus+ analyzer (Scil Animal Care, Tre-
viglio, Italy).
Cytofluorimetric analyses of PB were performed on a Becton Dickin-
son LSR II machine with BD FACSDiva software. PB from mice was
analyzed for hematopoietic reconstitution using the following anti-
bodies: phycoerythrin (PE)-conjugated anti-mouse CD11b, anti-
mouse CD3, and anti-mouse B220 (BD Biosciences, San Jose, CA).
Fluorescein isothiocyanate (FITC)-conjugated anti-mouse CD45.1
and allophycocyanin (APC)-conjugated anti-mouse CD45.2 anti-
bodies (BD Biosciences, San Jose, CA) were used to evaluate donor-
host chimerism at 16 weeks and termination.ber 2018
www.moleculartherapy.orgGenomic DNA was extracted from the blood for determination of
VCN at 16 weeks using the QIAamp DNA Mini Kit (QIAGEN,
Hilden, Germany).
Necropsy, Histology, and Pathology
Animals found dead during the study or sacrificed in poor condition
were subjected to necropsy, and selected tissues were harvested and
fixed in 10% neutral buffered formalin (Sigma-Aldrich, St. Louis,
MO). At termination, animals were shipped to Accelera (Nerviano,
Italy), where animals were sacrificed, and a full necropsy was executed
in compliance with the Italian GLP Regulations (DL 50; March 2,
2007; G.U. 8, April 13, 2007) and the OECD Principles of GLP (as
revised in 1997, ENV/MC/CHEM(98)17). Tissues were sent to
GlaxoSmithKline Research and Development for histology process-
ing, and pathological examination was performed in accordance
with United Kingdom GLP (statutory instruments number 3106
and 2004 number 994) and the OECD Principles of GLP (as revised
in 1997, ENV/MC/CHEM(98)17). In case of macroscopic lesions, a
part of the tissue was embedded in optimal cutting temperature
(O.C.T., Tissue-Tek Sakura) medium and frozen in liquid nitrogen
for possible further characterization.
The following organs were collected: adrenal gland, brain including
medulla and pons, cerebellar and cerebral cortex, epididymis, heart,
kidneys, large intestine (cecum, colon, and rectum), liver, lungs
with bronchi, lymph nodes (mesenteric and mandibular), ovaries
with oviduct, pancreas, skeletal muscle, skin, small intestine (duo-
denum, ileum, and jejunum), spleen, sternum with BM, stomach
with forestomach, testes, thymus, uterus, and vagina. Tissues were
embedded in paraffin wax, sectioned, mounted on glass slides, and
stained with H&E in accordance with GlaxoSmithKline (GSK) stan-
dard operation procedures (SOPs). Tissue reading was performed
at GSK Research and Development in accordance with GSK SOPs.
A histopathology peer review was carried out by a second pathologist
in accordance with GLP SR-Tiget SOPs.
For morphological analysis, 3-mm cryosections were fixed with 4%
paraformaldehyde and stained with H&E. For immunohistochemical
analysis, 3-mm cryosections were fixed with 4% paraformaldehyde at
room temperature and incubated with rat anti-mouse B220 (clone
RA3-6B2, Serotec), anti-mouse CD3 (clone CD3-12, Serotec), anti-
mouse F4/80 (clone CI, A3-1, AbD Serotec), and rabbit Ki67 (clone
SP6, Lab Vision) antibodies. 3-mm cryosections were fixed with
acetone at 4C and incubated with biotin-conjugated anti-mouse
CD45.1 (clone A20, BD Pharmingen) and with biotin-conjugated
anti-mouse CD45.2 (clone 104, BD Pharmingen). The immunoreac-
tions were revealed either by rat or rabbit on rodent HRP polymer
(Biocare Medical) by HRP-conjugated streptavidin and using diami-
nobenzidine (DAB) as chromogen (Biogenex, San Ramon). Slides
were counterstained with hematoxylin.
Approximately 500–800 mL of blood was collected from the aorta dur-
ing necropsy for chemical analyses. Glucose, urea, creatinine, triglyc-
erides, total protein, albumin, albumin-to-globulin ratio, globulinMolecular Th(calculated parameter), alkaline phosphatase, alanine aminotrans-
ferase, and aspartate aminotransferase were measured by Accelera.
Human CD34+ Cell Transduction and Xenotransplantation
Cryopreserved human cord blood CD34+ cells were purchased from
Lonza (Basel, Switzerland). Cells were thawed and seeded on non-
tissue culture-treated plates coated with Retronectin (30 mg/mL;
TaKaRa Bio, Shiga, Japan) () at 1  106 cells/mL in serum-free
CellGro stem cell growth medium (SCGM; Cell Genix Technologies,
Freiburg, Germany) in the presence of hSCF (300 ng/mL), hFLT3-L
(300 ng/mL), thrombopoietin (100 ng/mL), and interleukin-3 (IL-3;
60 ng/mL) (all from PeproTech, Rocky Hill, NY). Following 24 hr
of pre-stimulation, cells were transduced twice with GLOBE LV at
MOI 100.71 MOCK-transduced control cells were cultured under
the same conditions except for the presence of LV.
For transplantation studies in vivo, 2  105 transduced or MOCK-
transduced cells were administered to NSG mice (Jackson Labora-
tory) by injection in the lateral tail vein. Mice were maintained in a
specific pathogen-free animal facility. Procedures were performed
according to protocols approved by the Committee for Animal
Care and Use of San Raffaele Scientific Institute (Committee Protocol
537). 9- to 10-week-old NSG female mice were conditioned by a
sub-lethal dose of irradiation to provide depletion of endogenous
BM cells, allowing engraftment of human cells. The recipient mice
were exposed to 210 cGy of total body irradiation in an X-ray
Rad Source RS-2000 irradiator (Biological System). Prophylactic anti-
bacterial therapy was given by administration of gentamycin sulfate
80 mg/252 mL (0.3 mg/mL) by water intake from day1 to day +28.
Ex Vivo Analysis of Human Cells in Murine Tissues
After 12 weeks, mice were anesthetized and perfused by injecting
saline solution for approximately 30 min through blood vessels to
eliminate hematopoietic contamination from organs before sacrifice.
Mice were euthanized, and the BM, spleen, and thymus were collected
and analyzed for the presence of human CD45+ cells and the expres-
sion of different lineage-specific surface markers. DNA extracted
from cells and tissues was analyzed for VCN by qPCR.
p24 Assay
An HIV p24 ELISA (PerkinElmer, code NEK050) was performed on
serum (20–40 mL) of treated mice according to the manufacturer’s
instructions.
Statistical Analyses
GraphPad Prism was used to perform statistical analyses: one-way
ANOVA, post hoc Bonferroni’s multiple comparisons test or Stu-
dent’s t test, and two-tailed log rank Mantel-Cox test. A Z test for
proportion was performed for specific analyses.
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